Skip to content

Faeth Therapeutics, Inc.

SNSE

CIK 0001829802 · Pharmaceutical Preparations · Nasdaq

  • Sensei Biotherapeutics, Inc. (until 2026-06-16)
← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$186.61M
+30.1% YoY Q1 May 2026
EPS Diluted (TTM)
−$144.43
+30.4% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$37.37M
Q1 May 2026
Cash
$152.33M
Q1 May 2026
Total Debt
$567K
Q1 May 2026
Shares Outstanding
1.34M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings